ReWalk Robotics Ltd. (NASDAQ:LFWD – Get Free Report) Director Michael Swinford purchased 16,907 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was purchased at an average price of $1.83 per share, for a total transaction of $30,939.81. Following the acquisition, the director now owns 43,418 shares in the company, valued at approximately $79,454.94. This trade represents a 63.77 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Michael Swinford also recently made the following trade(s):
- On Wednesday, November 20th, Michael Swinford bought 16,471 shares of ReWalk Robotics stock. The shares were bought at an average price of $1.84 per share, for a total transaction of $30,306.64.
ReWalk Robotics Trading Down 0.5 %
Shares of NASDAQ:LFWD opened at $2.06 on Wednesday. ReWalk Robotics Ltd. has a one year low of $1.70 and a one year high of $9.10. The business’s fifty day moving average price is $2.56 and its two-hundred day moving average price is $3.50.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of ReWalk Robotics in a report on Wednesday, November 13th.
View Our Latest Analysis on ReWalk Robotics
Institutional Inflows and Outflows
An institutional investor recently bought a new position in ReWalk Robotics stock. Dimensional Fund Advisors LP bought a new position in ReWalk Robotics Ltd. (NASDAQ:LFWD – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned 0.16% of ReWalk Robotics at the end of the most recent quarter. 26.76% of the stock is currently owned by institutional investors.
ReWalk Robotics Company Profile
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
See Also
- Five stocks we like better than ReWalk Robotics
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- Best Aerospace Stocks Investing
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- What Do S&P 500 Stocks Tell Investors About the Market?
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.